Sk Biopharmaceuticals Co Ltd Capital Reinvestment Ratio
Sk Biopharmaceuticals Co Ltd capital reinvestment ratio. Sk Biopharmaceuticals Co Ltd (326030) has a Capital Reinvestment Ratio of 0.16x as of March 2026, meaning it reinvests 0% of its operating cash flow (₩17.92 Billion) in capital expenditures (₩2.94 Billion). See Sk Biopharmaceuticals Co Ltd (326030) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Sk Biopharmaceuticals Co Ltd (2024–2025)
Capital reinvestment ratio of Sk Biopharmaceuticals Co Ltd from 2024 to 2025. This chart tracks Sk Biopharmaceuticals Co Ltd's Capital Reinvestment Ratio across 2 annual periods. See 326030 financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Sk Biopharmaceuticals Co Ltd Capital Reinvestment Ratio by Year (2024–2025)
Sk Biopharmaceuticals Co Ltd capital reinvestment ratio by year from 2024 to 2025. For the full cash flow conversion analysis, see 326030 cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.17x | ₩176.33 Billion | ₩29.51 Billion | ▲ +18.3% |
| 2024 | 0.14x | ₩94.90 Billion | ₩13.42 Billion | — |